Finoriq research workspace
Immunovant, Inc. (IMVT) Historical Metrics
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs. Review IMVT fundamentals, ratios, and historical filing metrics on Finoriq.
Company Snapshot
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Company
- Immunovant, Inc. (IMVT)
- Ticker
- IMVT
- Market Cap
- $8.2B
- Latest Price
- $39.91
- Industry
- Biotech & Pharma
Immunovant, Inc. (IMVT) Current Valuation Metrics
Static valuation preview for Immunovant, Inc. (IMVT). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -6.2% | Net Income | TTM FY 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -5.0% | Operating Cash Flow | TTM FY 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 9.63x | Stockholders' Equity | FY 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.